Popular Sleep Gummies’ Hidden Withdrawal Warning

Vitamin and supplement bottles on store shelves — Photo: Sheila Fitzgerald / Shutterstock

A new mouse study finds that cannabinol, the sleep-friendly cannabis compound stuffed into millions of gummy bottles, can cause the brain to build tolerance and show withdrawal-like symptoms.

Quick Take

A peer-reviewed study found mice given repeated cannabinol (CBN) doses developed tolerance to several of its effects.
When researchers blocked cannabinoid receptors, CBN-treated mice showed withdrawal signs like head twitches and paw tremors.
The study used injected, high-dose CBN in mice over five days, not the oral gummies people actually buy.
Scientists and the university behind the research both say the results do not prove CBN causes dependence in humans.

What The Mouse Experiment Actually Found

Researchers gave adult mice cannabinol twice a day for five days, then ran a battery of behavior tests. The animals grew tolerant to CBN’s ability to cause catalepsy, dull pain, and drop body temperature. Published in Drug and Alcohol Dependence, the study also found cross-tolerance to another cannabinoid drug and showed CBN fully mimicked THC in one key test.

The most attention-grabbing part came on day six. Scientists gave the mice rimonabant, a drug that blocks cannabinoid receptors and can expose hidden withdrawal. CBN-treated mice suddenly showed head twitches, paw tremors, and frantic struggling during a tail-suspension test. Researchers at the University of Connecticut, who worked on the project, say the pattern mirrors withdrawal signs long seen with other cannabinoid compounds.

Cannabinol comes from aged THC and doesn’t get users high, which is exactly why gummy makers love it. It gets marketed as the gentle, legal cousin of THC, a natural off-switch for restless nights. This study is the first serious crack in that reputation, suggesting the body may adapt to CBN the same way it adapts to stronger cannabinoids.

Why This Isn’t Proof Of A Human Addiction Crisis

Every outlet covering the study, including the University of Connecticut itself, adds the same caveat. Mice are not people, and these findings do not prove CBN causes dependence or withdrawal in humans. Researcher Kinsey said plainly that more work is needed to understand how CBN behaves in people, especially at high doses or with long-term use.

There’s also a dosing gap worth taking seriously. The mice received CBN by injection, including doses as high as 100 milligrams per kilogram of body weight, far removed from a chewable gummy swallowed before bed. The experiment also lasted just five days. Nobody has tested what months of nightly gummy use does to the human brain, because that study simply hasn’t been run yet.

Human research on CBN remains thin and short. A randomized insomnia trial found no serious side effects, but the authors admitted the study ran too briefly to judge long-term safety. Another review found no completed human trials have ever measured CBN’s psychiatric effects, calling the overall safety data limited. A separate placebo-controlled trial of oral CBN capsules found no meaningful difference in side effects compared to placebo.

The Bigger Pattern Behind Cannabis Research

This fits a familiar script in cannabinoid science. Animal studies raise a red flag years before human trials catch up, and the gap gets filled with marketing on one side and alarm on the other. Cannabis withdrawal itself is well documented in people, with one major analysis of over 23,000 participants estimating that 47 percent of regular cannabis users experience withdrawal symptoms when they stop.

Popular Sleep Supplement Cannabinol Could Come With an Unexpected Catch – Dependence, Scientists Warn | University of Connecticut, SciTechDaily

A cannabis compound sold to help people sleep caused withdrawal symptoms in mice after just three days of repeated use.

Researchers at… pic.twitter.com/cl4l4jalPg

— Owen Gregorian (@OwenGregorian) October 25, 2026

That history matters here. Tolerance, physical dependence, and addiction are three different things, and conflating them does nobody favors. This study shows tolerance and withdrawal-like signs in mice, not proof that grandma’s sleep gummy is secretly addictive. Common sense says treat it as an early warning, not a verdict, and expect the Food and Drug Administration and independent labs to take a harder look at what’s actually sold on store shelves.

For now, nothing requires a label change or a recall, and no federal health warning has followed the study’s publication. Consumers reaching for CBN gummies at bedtime aren’t doing anything reckless based on current evidence. But a product marketed as gentle and natural deserves the same scrutiny as any drug that alters brain chemistry, especially one millions of Americans now take nightly without a second thought.